Patient group funding
Patient groups – non-profit organisations founded by patients, care-givers, family members and health professionals – are important stakeholders for GSK.
They engage with healthcare providers, governments, the media, and patients to promote improved treatment and services for patients. They also campaign on issues that affect patients’ and care-givers’ lives, including increasing access to quality medicines, services and information on disease. Some carry out research into the causes of and potential treatments for specific conditions.
Pan European
During 2018, we provided financial support to the following pan European patient groups:
Alzheimer Europe (AE) (PDF)
European Federation of Allergy and Airways Disease Patients Association (PDF)
European Patients' Forum (PDF)
European Organisation for Rare Diseases (EURORDIS) (PDF)
LUPUS EUROPE (PDF)
National European
Details of funding provided to patient groups across Europe can be found on the relevant country website. Where no country website currently exists, and for those GSK local operating companies that supported patient groups in 2018, the information is either published directly on this page or in a booklet available from the local office.
Countries with websites
Austria
Belgium
Bulgaria
Czech Republic
Finland
France
Germany
Greece
Ireland
Italy
Norway
Poland
Romania
Slovakia
Slovenia
Spain
Sweden
Switzerland
Countries without websites
Hungary (PDF)
Israel (PDF)
Latvia (PDF)
Lithuania (PDF)
Portugal (PDF)
UK
During 2018, we provided support to the following UK patient groups:
British Lung Foundation (PDF)
Jo's Cervical Cancer Trust (PDF)
Meningitis Now (PDF)
Muscular Dystrophy UK (PDF)
Sickle Cell Society (PDF)
Theodora's Children's Charity (PDF)
Action for Pulmonary Fibrosis (PDF)
Alzheimer’s Society (PDF)
GSK also provides funding to support UK community healthcare charities through the GSK IMPACT Awards, in partnership with The King’s Fund. This annual programme recognises and promotes excellence in community healthcare, providing funding and training to help strengthen the award winners’ current management plans and support their future aspirations. Find out more about our Impact Awards.
Back to topEmerging Markets and Intercontinental
During 2018 we provided funding to the following emerging markets and intercontinental patient groups:
Countries with PDFs
Argentina (PDF)
Colombia (PDF)
Hong Kong (PDF)
New Zealand (PDF)
Countries without PDFs
Australia
Brazil
Canada
Korea
Mexico
Russia
Taiwan
Turkey
Global
During 2018, we provided financial support to the following global patient groups:
Confederation of Meningitis Organisations (CoMO) (PDF)
International Alliance of Patient Organisations (IAPO) (PDF)
Global Asthma and Allergy Patient Platform (GAAPP) (PDF)
COPD Foundation (PDF)
Meningitis Research Foundation (PDF)
